Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00052000 · ClinicalTrials.gov registry record · Phase 1
A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00052000 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 29 participants.
The verdict
NCT00052000, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is the first study of MLN2704 administered to humans. The purpose of the study is to determine the highest dose of MLN2704 that can be given safely to patients with prostate cancer, and to identify any side effects associated with taking the drug. This study will also evaluate how MLN2704 is taken up (absorbed), broken down (metabolized) and eliminated (excreted) by the body. This process is called pharmacokinetic analysis.
Interventions
- DRUG MLN2704 (DM1 conjugated monoclonal antibody MLN591)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2002-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00052000
The ClinicalTrials.gov registry entry for NCT00052000 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MLN2704 (DM1 conjugated monoclonal antibody MLN591) is the first listed.
NCT00052000 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00052000 about?
NCT00052000 is a clinical study titled "A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer". This is the first study of MLN2704 administered to humans. The purpose of the study is to determine the highest dose of MLN2704 that can be given safely to patients with prostate cancer, and to identify any side effects associated with taking the drug. This study will also evaluate how MLN2704 is ta...
What is the current status of trial NCT00052000?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2002-11.
What interventions are being tested in trial NCT00052000?
The interventions under investigation include: MLN2704 (DM1 conjugated monoclonal antibody MLN591) (DRUG).
Who is sponsoring clinical trial NCT00052000?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.